Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Phase 1 Completed 21 enrolled Darell D. Bigner, MD, PhD National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody after radiation therapy in treating patients with newly diagnosed primary brain tumors that can be surgically resected.

Timeline

Start: 1997-09
Primary completion: 2003-11
Completion: 2010-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Irinotecan	Small molecule	—	Intravenous
Background	carmustine	Small molecule	—	Intravenous

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Summary

Timeline

Drugs

Indications